LOXL1-AS1 overexpression was found to be favorable prognostic biomarker in adrenocortical carcinoma, uterine corpus endometrial carcinoma, and uveal melanoma, and to be unfavorable prognostic biomarker in cholangio carcinoma, glioblastoma multiforme, kidney renal clear cell carcinoma, brain lower grade glioma, mesothelioma, and pancreatic adenocarcinoma. Here, LOXL1 is linked to pancreatic adenocarcinoma.